Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Seizures in Lupus

Anna Helena Jonsson, MD, PhD, and Shamik Bhattacharyya, MD  |  Issue: March 2015  |  March 1, 2015

NPSLE

Despite the best efforts of experts in the field, NPSLE remains vaguely defined. In 1999, an ad hoc committee assembled by the ACR produced formal definitions of 19 NPSLE syndromes, ranging from headache to cerebrovascular disease.1 Unfortunately, although these definitions have been important for providing uniform nomenclature among researchers, numerous other diseases can cause presentations identical to each NPSLE syndrome. Many complications of SLE, such as uremia caused by lupus nephritis, and medications used to treat SLE can themselves cause neurological disease, which could be considered forms of secondary NPSLE. All in all, CNS symptoms in a patient with SLE are often a diagnostic conundrum with a very broad differential diagnosis.

Primary NPSLE is thought to occur via one of two possible types of mechanisms.2 The better understood of these is vascular insult, in which antiphospholipid antibodies or other risk factors for hypercoagulation lead to thrombi and focal regions of ischemia, causing clinical presentations, such as stroke or seizure. There may also be additional small vessel injury in chronic disease resulting in vasculopathy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The second mechanism, inflammatory NPSLE, is poorly understood. Autopsy studies on patients with SLE have shown that CNS vasculitis is very, very rare. Instead, it is thought that inflammation may be mediated through antineuronal antibodies or cytokine injury (Note: Elevated levels of interleukin 6 in SLE correlate with increased risk of seizures).2

So far, no particular serological marker has proved to be predictive of NPSLE. Presence of antiribosomal P was proposed to be such a marker. Subsequent studies, however, estimate its sensitivity at 26% and specificity at 80%, limiting the utility of this test.3 With the diverse pathogenic mechanisms causing NPSLE, there may not be a single predictive marker. Elucidating the pathophysiology of the many NPSLE syndromes will be crucial in developing a better framework for its diagnosis and treatment.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Diagnosis

Because the possible neuropsychological effects of lupus are broad and can affect both the central and peripheral nervous systems, the diagnostic workup is guided by anatomic localization and clinical suspicion. The workup will uniformly require basic labs—especially because metabolic derangements are a common cause of neurological disease—as well as imaging.

For acute presentations, such as seizures, an immediate head CT without contrast is necessary to rule out hemorrhage or other severe structural disease. For most cases of neuropsychiatric disease in the SLE population, a magnetic resonance imaging (MRI) of the brain will also be indicated. Functional imaging (e.g., positron emission tomography [PET] or functional MRI [fMRI]) has shown promise in recent studies, particularly for cognitive dysfunction, but the findings are not specific for NPSLE.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:ClinicalDiagnosisLupusneuropsychiatricrheumatologyseizureTreatment

Related Articles

    Lupus in the Child’s Mind

    March 1, 2009

    Unique neuropsychiatric problems require a unique approach

    Childhood-onset Lupus Brings Distinct Challenges at Each Phase of Life

    January 1, 2014

    Differences in disease manifestations, severity, and management require special consideration from rheumatologists who treat children and adolescents with systemic lupus erythematosus

    Reading Rheum

    August 1, 2007

    Handpicked Reviews of Contemporary Literature

    Rheumatic Disease Manifestations in the Central Nervous System

    January 19, 2016

    SAN FRANCISCO—Let’s say your radiologist comes to you and says that an angiogram gives a diagnosis of CNS vasculitis on four patients, all with acute onset of headache and stroke: One is a 25-year-old woman who is three months pregnant. Another is a 50-year-old man using excessive doses of nasal decongestants. Another is a 40-year-old…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences